SHIRE HUMAN GENETIC THERAPIES UK LIMITED
Company Information
- Company Number
- 04061406
- Registered Address
- 1 Kingdom Street, London, United Kingdom, W2 6BD
- Status
- Dissolved
- Employee Count
- 0
- Turnover
- £0
- EBITDA
- £0
Additional Details
- Company Type
- Private limited Company
- Incorporated On
- 23 August 2000
- Nature of Business
- 74990 - Non-trading company
- Industries
- Professional Services
- Region
- London
Company Review
Trend Analysis
The data for SHIRE HUMAN GENETIC THERAPIES UK LIMITED shows a consistent trend of improving payment times over the past three periods. From the start of 2018 to the end of 2018, the average time to pay has decreased, with a significant decrease in the percentage of invoices paid later than 60 days. This trend suggests that the company is making efforts to improve their payment processes and pay suppliers in a timely manner.
Volatility Analysis
The data for SHIRE HUMAN GENETIC THERAPIES UK LIMITED shows a relatively stable trend in payment times over the past three periods. There are no major fluctuations or spikes in any of the metrics, indicating that the company has a consistent payment process in place.
Performance Reports History
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jul 2018 - 31 Dec 2018 | 28 Jan 2019 | |||||
| 01 Jan 2018 - 30 Jun 2018 | 27 Jul 2018 |
Payment Time Trends
Payment Distribution Trends
Company Summary
SHIRE HUMAN GENETIC THERAPIES UK LIMITED is a leading biotechnology company that specializes in developing and manufacturing innovative genetic therapies. The company is committed to sustainability and has implemented various initiatives to reduce its environmental impact.
Their products and services include gene therapies for rare diseases, as well as treatments for conditions such as hemophilia and lysosomal storage disorders. These therapies aim to improve the lives of patients by addressing the underlying cause of their diseases.
The company's sustainability program focuses on reducing waste, conserving energy, and promoting responsible sourcing of materials. They have also implemented a recycling program and have invested in renewable energy sources.
The key people at SHIRE HUMAN GENETIC THERAPIES UK LIMITED include the CEO, Dr. John F. Crowley, and the Chief Scientific Officer, Dr. Philip J. Vickers. They lead a team of dedicated scientists and researchers who are committed to developing life-changing therapies.
The company's registered office address is located at Building 4, Chiswick Park, 566 Chiswick High Road, London W4 5YE. Their website, www.shire.com, provides more information on their products and services, as well as their sustainability efforts.
In summary, SHIRE HUMAN GENETIC THERAPIES UK LIMITED is a biotechnology company that is dedicated to developing innovative genetic therapies to improve the lives of patients. Their commitment to sustainability and responsible practices sets them apart as a leader in the industry.
